Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Situ Vaccination With Flt3L, Radiation, Poly-ICLC, and Pembrolizumab in iNHL, MBC, and HNSCC
NCT03789097Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Apr 2019
- Primary completion
- Dec 2023
- Modality
- Antisense DNA, Immune Checkpoint Inhibitors, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, Flt3 ligand, poly iclc in non-Hodgkin lymphoma (NHL), breast cancer, head and neck squamous cell carcinoma (HNSCC), sponsored by Icahn School of Medicine at Mount Sinai. Started Apr 2019; status: completed.
02
Drugs
03
Conditions
non-Hodgkin lymphoma (NHL)breast cancerhead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03789097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03789097.